(Informaci\u00f3n remitida por la empresa firmante)<\/p>\n
\n\u00b7 Gr\u00fcnenthal acquires the pharmaceutical company Valinor Pharma, further strengthening Gr\u00fcnenthal’s footprint in the United States.<\/p>\n
\n\u00b7 With the acquisition, Gr\u00fcnenthal becomes the global owner of Movantik* \/ Moventig* (naloxegol).<\/p>\n
\n\u00b7 Since 2017, Gr\u00fcnenthal has invested more than \u20ac2 billion in successful M&A transactions, significantly strengthening its profitability.<\/p>\n
NEWS AKTUELL \/\/ Aachen, Germany, 22 July 2024 – Gr\u00fcnenthal today announced the acquisition of US-based Valinor Pharma, LLC (\u00abValinor\u00bb) and its product Movantik* (naloxegol), with a total deal value of approx. $250 million inclusive of all royalty obligations. Gr\u00fcnenthal will finance the transaction using available liquidity.<\/p>\n
Movantik* is indicated for the oral treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain. The transaction further expands Gr\u00fcnenthal’s portfolio of established medicines and adds to the company’s growing U.S. business. Gross sales from Movantik* in the United States reached over $200 million in 2023.<\/p>\n
\u00abAs a pain specialist, Movantik is a perfect fit for Gr\u00fcnenthal with our existing customer base and complementary product portfolio\u00bb, says Gabriel Baertschi, CEO, Gr\u00fcnenthal. \u00abThe acquisition of Valinor Pharma strengthens our footprint in the United States, the most important growth market for Gr\u00fcnenthal.\u00bb<\/p>\n
\nMarv Kelly, President of Gr\u00fcnenthal US, commented: \u00abWe are excited to welcome Valinor and expand our portfolio offering to pain specialists with Movantik.\u00bb<\/p>\n
\nGr\u00fcnenthal acquired the product in Europe (branded Moventig* outside of the U.S.) in 2023 as part of a joint venture with Kyowa-Kirin. The acquisition of Valinor makes Gr\u00fcnenthal the worldwide owner of the brand (ex-Canada).<\/p>\n
With Movantik*, Gr\u00fcnenthal continues to execute its strategy of acquiring established medicines to expand its portfolio and increase the company’s profitability. Since 2017, Gr\u00fcnenthal has acquired several established medicines, including NebidoTM, the European rights to CrestorTM and NexiumTM, as well as the global rights to VimovoTM (excluding the U.S. and Japan), QutenzaTM and ZomigTM (excluding Japan). In 2023, Gr\u00fcnenthal established Gr\u00fcnenthal Meds, a joint venture with Kyowa Kirin International, which manages a portfolio of 13 brands primarily focused on pain management. Gr\u00fcnenthal has invested more than \u20ac2 billion in successful M&A transactions.<\/p>\n
About Gr\u00fcnenthal<\/p>\n
\nGr\u00fcnenthal is a global leader in pain management and related diseases. As a science-based, fully integrated pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better, and innovation is our passion. We are focusing all our activities and efforts on working towards our vision of a world free of pain.<\/p>\n
\nGr\u00fcnenthal is headquartered in Aachen, Germany, and has affiliates in 27 countries across Europe, Latin America, and the U.S. Our products are available in approx. 100 countries. In 2023, Gr\u00fcnenthal employed around 4,400 people and achieved revenues of \u20ac1.8 billion.<\/p>\n
More information: www.grunenthal.com and Gr\u00fcnenthal Report 2023\/24<\/p>\n
\nFollow us on:<\/p>\n
\nLinkedIn: Grunenthal Group<\/p>\n
\nInstagram: grunenthal<\/p>\n
\nFor further information, please contact:<\/p>\n
\nFlorian Dieckmann, Head Global Corporate Affairs<\/p>\n
\nflorian.dieckmann@grunenthal.com<\/p>\n","protected":false},"excerpt":{"rendered":"
(Informaci\u00f3n remitida por la empresa firmante) \u00b7 Gr\u00fcnenthal acquires the pharmaceutical company Valinor Pharma, further strengthening Gr\u00fcnenthal’s footprint in the United States. \u00b7 With the acquisition, Gr\u00fcnenthal becomes the global owner of Movantik* \/ Moventig* (naloxegol). \u00b7 Since 2017, Gr\u00fcnenthal has invested more than \u20ac2 billion in successful M&A transactions, significantly strengthening its profitability. NEWS […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[],"class_list":["post-54260","post","type-post","status-publish","format-standard","hentry","category-noticias"],"_links":{"self":[{"href":"https:\/\/webciudadana.net\/index.php?rest_route=\/wp\/v2\/posts\/54260","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/webciudadana.net\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/webciudadana.net\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/webciudadana.net\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/webciudadana.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=54260"}],"version-history":[{"count":0,"href":"https:\/\/webciudadana.net\/index.php?rest_route=\/wp\/v2\/posts\/54260\/revisions"}],"wp:attachment":[{"href":"https:\/\/webciudadana.net\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=54260"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/webciudadana.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=54260"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/webciudadana.net\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=54260"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}